Featured Research

from universities, journals, and other organizations

No Need For Needles: Botox Sponge Treats Intrinsic Rhinitis

Date:
October 16, 2009
Source:
BioMed Central
Summary:
Injecting botulinum toxin (botox) to treat intrinsic or allergic rhinitis may be a thing of the past as researchers have now shown that sponges soaked in botox are equally effective in treating the condition. The research offers a potential needle-free treatment to the millions of people who suffer from rhinitis.

Injecting botulinum toxin (botox) to treat intrinsic or allergic rhinitis may be a thing of the past as researchers have now shown that sponges soaked in botox are equally effective in treating the condition. The research, published in BioMed Central's open access journal Head & Face Medicine, offers a potential needle-free treatment to the millions of people who suffer from rhinitis.

Rainer Laskawi (ENT-Department) worked with a team of researchers from the University Medical Center Gφttingen, Germany, to test the effectiveness of the botox sponge. He said, "Intrinsic rhinitis affects a lot of patients and can be quite disabling for the patient. Botox injections can help, and we wanted to explore a less invasive alternative".

The researchers inserted sponges into the patients' nostrils for 30 minutes, which were soaked with botox directly after the insertion. The patients then kept a 'nose diary' for the next twelve weeks, detailing sneezes per day, tissues used and a 'congestion score'. A group of patients who received the treatment scored better on all aspects. According to Laskawi, "We've shown that the minimally invasive application method of BTA with a sponge is a safe, painless method which can lead to a long lasting reduction of nasal hypersecretion".

It may be hypothized that there exits a certain form of a "botulinum toxin-sensitive" intrinsic rhinitis.


Story Source:

The above story is based on materials provided by BioMed Central. Note: Materials may be edited for content and length.


Journal Reference:

  1. Saskia Rohrbach, Katharina Junghans, Sibylle Kφhler and Rainer Laskawi. Minimally invasive application of botulinum toxin A in patients with idiopathic rhinitis. Head & Face Medicine, 2009; (in press) [link]

Cite This Page:

BioMed Central. "No Need For Needles: Botox Sponge Treats Intrinsic Rhinitis." ScienceDaily. ScienceDaily, 16 October 2009. <www.sciencedaily.com/releases/2009/10/091015191703.htm>.
BioMed Central. (2009, October 16). No Need For Needles: Botox Sponge Treats Intrinsic Rhinitis. ScienceDaily. Retrieved October 1, 2014 from www.sciencedaily.com/releases/2009/10/091015191703.htm
BioMed Central. "No Need For Needles: Botox Sponge Treats Intrinsic Rhinitis." ScienceDaily. www.sciencedaily.com/releases/2009/10/091015191703.htm (accessed October 1, 2014).

Share This



More Health & Medicine News

Wednesday, October 1, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Some Positive Ebola News: Outbreak 'Contained' In Nigeria

Newsy (Sep. 30, 2014) — The CDC says a new case of Ebola has not been reported in Nigeria for more than 21 days, leading to hopes the outbreak might be nearing its end. Video provided by Newsy
Powered by NewsLook.com
UN Ebola Mission Head: Immediate Action Is Crucial

UN Ebola Mission Head: Immediate Action Is Crucial

AFP (Sep. 30, 2014) — The newly appointed head of the United Nations Mission for Ebola Emergency Response (UNMEER), Anthony Banbury, outlines operations to tackle the virus. Duration: 00:39 Video provided by AFP
Powered by NewsLook.com
CDC Confirms First Case of Ebola in US

CDC Confirms First Case of Ebola in US

AP (Sep. 30, 2014) — The CDC has confirmed the first diagnosed case of Ebola in the United States. The patient is being treated at a Dallas hospital after traveling earlier this month from Liberia. (Sept. 30) Video provided by AP
Powered by NewsLook.com
New Breast Cancer Drug Extends Lives In Clinical Trial

New Breast Cancer Drug Extends Lives In Clinical Trial

Newsy (Sep. 30, 2014) — In a clinical trial, breast cancer patients lived an average of 15 months longer when they received new drug Perjeta along with Herceptin. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins